A5082506728- Urinary Tract Infections Management
- Venous Thromboembolism Diagnosis and Management
- Pediatric Urology and Nephrology Studies
- Atrial Fibrillation Management and Outcomes
- Urinary Bladder and Prostate Research
- Central Venous Catheters and Hemodialysis
- Medication Adherence and Compliance
- Mobile Health and mHealth Applications
- Blood Pressure and Hypertension Studies
- Pharmaceutical Practices and Patient Outcomes
- Economic and Financial Impacts of Cancer
- Peripheral Artery Disease Management
- Health and Medical Research Impacts
- Health Systems, Economic Evaluations, Quality of Life
- Antibiotics Pharmacokinetics and Efficacy
- Blood Coagulation and Thrombosis Mechanisms
- Bacterial Identification and Susceptibility Testing
- Cardiac Arrhythmias and Treatments
- Chemotherapy-related skin toxicity
- Cancer Treatment and Pharmacology
- Biomedical Ethics and Regulation
Janssen (United States)
2007-2025
Janssen Scientific Affairs (United States)
2007-2025
Johnson & Johnson (United States)
2024
Ambulatory patients receiving systemic cancer therapy are at varying risk for venous thromboembolism. However, the benefit of thromboprophylaxis in these is uncertain.In this double-blind, randomized trial involving high-risk ambulatory with (Khorana score ≥2, on a scale from 0 to 6, higher scores indicating thromboembolism), we randomly assigned without deep-vein thrombosis screening receive rivaroxaban (at dose 10 mg) or placebo daily up 180 days, every 8 weeks. The primary efficacy end...
The impact of using direct-to-consumer wearable devices as a means to timely detect atrial fibrillation (AF) and improve clinical outcomes is unknown. Heartline pragmatic, randomized, decentralized application-based trial US participants aged ≥65 years. Two randomized cohorts include adults with possession an iPhone without history AF those diagnosis taking direct oral anticoagulant (DOAC) for ≥30 days. Participants within each cohort are (3:1) either core digital engagement program (CDEP)...
Objective: A double-blind, noninferiority trial was conducted to establish the safety and efficacy of a once-daily, 5-day course levofloxacin 750 mg compared twice-daily, 10-day ciprofloxacin in complicated urinary tract infections (cUTI) acute pyelonephritis (AP). This report focuses on subjects with AP.Research design methods: Adult male female clinical signs symptoms AP laboratory confirmation their diagnosis were randomized receive one dose once daily intravenously (IV) or orally placebo...
Abstract Background Pancreatic cancer patients are at risk for venous thromboembolism (VTE); the value of thromboprophylaxis has not been definitively established. Methods This trial randomized initiating a new regimen and high VTE (Khorana score ≥2) to rivaroxaban 10 mg or placebo up day 180. analysis examined subset pancreatic patients. The primary efficacy endpoint was composite symptomatic deep‐vein thrombosis (DVT), asymptomatic proximal DVT, any pulmonary embolism, VTE‐related death....
Background Care4Today is a digital health platform developed by Johnson & comprising patient mobile app (Care4Today Connect), care provider (HCP) portal, and an educational website. It aims to improve medication adherence; enable self-reporting of experiences; provide education; enhance connection with HCPs; facilitate data analytics learning across disease areas, including cardiovascular disease. Objective This study aimed gather feedback on Connect, specifically the coronary artery...
Abstract Introduction In the CASSINI study, rivaroxaban thromboprophylaxis significantly reduced primary venous thromboembolism (VTE) endpoints during intervention period, but several thromboembolic events designated as secondary efficacy were not included in analysis. This study was aimed to evaluate full impact of on all prespecified occurring study. Methods a double-blind, randomized, placebo-controlled adult ambulatory patients with cancer at risk for VTE (Khorana score ≥2). Patients...
4016 Background: Rivaroxaban thromboprophylaxis has been shown to reduce venous thromboembolism (VTE) on-treatment in ambulatory cancer patients a recent randomized trial. Pancreatic are at substantial risk for VTE; value of not definitively established. Methods: CASSINI was double-blind placebo-controlled trial initiating new regimen, high VTE (Khorana score ≥2), rivaroxaban 10 mg daily or placebo up 180 days. Patients were stratified by presence absence pancreatic cancer. had screening...
Background: Decentralized clinical trials using direct-to-participant recruitment can potentially engage large, representative participant pools. Research Question: Can a decentralized trial use multichannel approach to recruit patients >65 years old across the United States? Goals/Aims: To share insights on strategies for in decentralized, app-based Heartline study. Methods: is randomized testing impact of mobile heart health program with electrocardiogram (ECG) and Irregular Rhythm...
ABSTRACT Introduction Coronary artery disease (CAD) and peripheral (PAD) increase the risks of cardiovascular events death. Digital health technologies are rapidly expanding to improve healthcare quality access. The Care4Today Connect (C4T CAD‐PAD) mobile application is designed help patients with CAD and/or PAD medication adherence, learn about their disease, make lifestyle modifications, enhance provider (HCP) connection via an HCP‐facing portal. Hypothesis & Methods prospective,...
<sec> <title>BACKGROUND</title> Care4Today is a digital health platform developed by Johnson &amp; comprising patient mobile app (Care4Today Connect), care provider (HCP) portal, and an educational website. It aims to improve medication adherence; enable self-reporting of experiences; provide education; enhance connection with HCPs; facilitate data analytics learning across disease areas, including cardiovascular disease. </sec> <title>OBJECTIVE</title> This study aimed gather feedback...
You have accessJournal of UrologyPodium 2, Saturday, May 19, 2007 1:00 - 3:00 pm1 Apr 200761: Double-Blind, Randomized Comparison Levofloxacin 750 MG once Daily for 5 Days and Ciprofloxacin Twice 10 in the Treatment Complicated Urinary Tract Infection Acute Pyelonephritis Mohammed Khashab, Janet Peterson, Simrati Kaul, Alan C. Fisher, James B. Kahn KhashabMohammed Khashab More articles by this author , PetersonJanet Peterson KaulSimrati Kaul FisherAlan Fisher KahnJames View All Author...